Key facts
- This page summarizes Matthew Ferguson's Form 4 filing for ELUTIA INC. (ELUT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Sep 2023, 16:50.
Matthew Ferguson - 21 Sep 2023 Form 4 Insider Report for ELUTIA INC. (ELUT)
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- ELUT
- Reported as of
- 21 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Sep 2023, 16:50:34 UTC
- Prior SEC filing
- 09 Mar 2023
- Next SEC filing
- 02 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Ferguson filed Form 4 for ELUTIA INC. (ELUT) on 21 Sep 2023.
Change
- Previous filing in this sequence was filed on 09 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AZYO
transaction
Class A Common Stock
Award
- Transaction value
- Shares
- +70,053
- Change %
- +139%
- Price
- Shares after
- 120,519
- Date
- 21 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AZYO
transaction
Derivative
Warrants (rights to buy)
Award
- Transaction value
- Shares
- +105,080
- Change %
- Price
- Shares after
- 105,080
- Date
- 21 Sep 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 105,080
- Exercise price
- $1.43
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock.
Footnote F2
Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
Footnote F3
The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028.